Li Ling, Duns Gregory J, Dessie Wubliker, Cao Zhenmin, Ji Xiaoyuan, Luo Xiaofang
Hunan Engineering Technology Research Center for Comprehensive Development and Utilization of Biomass Resources, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, China.
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China.
Front Pharmacol. 2023 Jan 30;14:1052301. doi: 10.3389/fphar.2023.1052301. eCollection 2023.
Breast cancer is the leading cause of cancer-related fatalities in female worldwide. Effective therapies with low side effects for breast cancer treatment and prevention are, accordingly, urgently required. Targeting anticancer materials, breast cancer vaccines and anticancer drugs have been studied for many years to decrease side effects, prevent breast cancer and suppress tumors, respectively. There are abundant evidences to demonstrate that peptide-based therapeutic strategies, coupling of good safety and adaptive functionalities are promising for breast cancer therapy. In recent years, peptide-based vectors have been paid attention in targeting breast cancer due to their specific binding to corresponding receptors overexpressed in cell. To overcome the low internalization, cell penetrating peptides (CPPs) could be selected to increase the penetration due to the electrostatic and hydrophobic interactions between CPPs and cell membranes. Peptide-based vaccines are at the forefront of medical development and presently, 13 types of main peptide vaccines for breast cancer are being studied on phase III, phase II, phase I/II and phase I clinical trials. In addition, peptide-based vaccines including delivery vectors and adjuvants have been implemented. Many peptides have recently been used in clinical treatments for breast cancer. These peptides show different anticancer mechanisms and some novel peptides could reverse the resistance of breast cancer to susceptibility. In this review, we will focus on current studies of peptide-based targeting vectors, CPPs, peptide-based vaccines and anticancer peptides for breast cancer therapy and prevention.
乳腺癌是全球女性癌症相关死亡的主要原因。因此，迫切需要副作用小的有效乳腺癌治疗和预防疗法。多年来，人们一直在研究靶向抗癌材料、乳腺癌疫苗和抗癌药物，以分别减少副作用、预防乳腺癌和抑制肿瘤。有大量证据表明，基于肽的治疗策略结合了良好的安全性和适应性功能，对乳腺癌治疗很有前景。近年来，基于肽的载体因其与细胞中过表达的相应受体的特异性结合而受到关注，用于靶向乳腺癌。为了克服内化效率低的问题，可以选择细胞穿透肽（CPP），由于CPP与细胞膜之间的静电和疏水相互作用来增加穿透率。基于肽的疫苗处于医学发展的前沿，目前，13种主要的乳腺癌肽疫苗正处于III期、II期、I/II期和I期临床试验阶段。此外，包括递送载体和佐剂在内的基于肽的疫苗也已投入使用。最近，许多肽已用于乳腺癌的临床治疗。这些肽表现出不同的抗癌机制，一些新型肽可以逆转乳腺癌对敏感性的耐药性。在这篇综述中，我们将重点关注基于肽的靶向载体、CPP、基于肽的疫苗和抗癌肽在乳腺癌治疗和预防方面的当前研究。
